HER2 Support Group Forums

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)
-   Clinical Trials (https://her2support.org/vbulletin/forumdisplay.php?f=29)
-   -   While we wait on information for the Neuvax Her2 3+ trial . . . (https://her2support.org/vbulletin/showthread.php?t=62178)

'lizbeth 11-18-2014 08:44 AM

While we wait on information for the Neuvax Her2 3+ trial . . .
a reminder that there is one for the lower expressors that is currently enrolling.

If you know of anyone who is newly diagnosed as a "triple negative" or 'Her2 negative" PLEASE share about this trial and encourage them to look into it. The interim data has been very promising and participants have had the good fortune of remaining cancer free in the vaccine arm for 48 months.

So think of anyone who you know in the community, support groups, church, school, etc and let them know to look into this vaccine.


Experimental: Herceptin + NeuVax vaccine
Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine (E75 peptide 1000mcg + GM-CSF 250mcg) administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF. After completion of primary vaccine series, patients will receive four NeuVax vaccine booster inoculations to be administered at 12, 18, 24, and 30 months from date of first Herceptin infusion.

MargaretAlice 11-24-2014 12:59 PM

Re: While we wait on information for the Neuvax Her2 3+ trial . . .

The NeuVax clinical trial will be led by Elizabeth Mittendorf.

2011-0595(clinicaltrials.gov NCT No: NCT01479244) Title:PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive
Breast Cancer with Low to Intermediate HER2 Expression with
NeuVax Treatment
Principal Investigator:Elizabeth A. Mittendorf Treatment Agent:GM-CSF; NeuVax Study Status:Open Study Description:The goal of this part of the clinical research study is to learn more about the
amounts of the HER2 protein in patients who had breast cancer using the Bond
Oracle HER2 IHC System.

All times are GMT -7. The time now is 04:40 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2022, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021